Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, non-comparative, three-arm, phase IIa trial of Ipatasertib
(GDC-0068) in combination with non-taxane chemotherapy agents for taxane-pretreated
unresectable locally advanced or metastatic triple-negative breast cancer patients